- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2025 · career development · Career Development Award
From surviving to thriving: evaluation of food insecurity and a 'food is medicine' intervention in childhood cancer survivors
Rahela Aziz-Bose · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2025 · research · BCRF-AACR CDA to Promote Diversity and Inclusion
Developing a Multi-Modal Breast Cancer Stigma Mitigating Intervention in Rwanda
Temidayo A Fadelu · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2025 · career development · Young Investigator Award
Screening the Pancreatic Adenocarcinoma Secretome for New Immunotherapy Targets
Jordan Chinai · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2025–2030 · research · R35
Empowering NMR Utilization in Mechanistic Biology: Extending Size Limits and Catalyzing Automation
Haribabu Arthanari · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2029 · research · R35
Molecular mechanisms of DNA double strand break repair by homologous recombination
Benjamin M Stinson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2027 · career development · K99
Signaling pathways in tumoricidal macrophages in pancreatic cancer
Li Qiang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2027 · research · R21
Targeting the CDK4/6 pathway in MiT/TFE-translocation renal cell carcinoma
Srinivas Raghavan Viswanathan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2030 · cooperative agreement · U01
Characterizing genetic risk of cancer across diverse populations through multi-ancestry epigenome profiling and chromatin QTL discovery
Sylvan C. Baca · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2029 · research · R01
Dissecting CCL5 contribution to antigen specific T cell responses in head and neck cancers
Scott J Rodig · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2027 · career development · K01
The mechanistic study on irisin-mediated immune response and its role in adipose tissue dynamics
Mu A · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2027 · career development · K99
Dissecting the impact of tumor-immune spatial interactions in mismatch-repair stratified colorectal cancers
Jeremiah Wala · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2027 · research · R37
Molecular mechanisms underlying lineage plasticity in prostate cancer
Himisha Beltran · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2030 · research · R01
Targeting iron metabolism in pancreatic adenocarcinoma to overcome KRAS inhibitor therapeutic resistance
Joseph D Mancias · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2030 · career development · K08
Immune Evasion through HLA-E in Diffuse Large B-Cell Lymphoma: Defining Its Regulation and Cellular Interactions
Cynthia Hahn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2029 · research · R01
Cellular and Biochemical Pathways of Adipose Metabolism and Thermogenesis
Bruce M. Spiegelman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2029 · career development · K00
Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma
Amanda Johnson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2027 · fellowship · F32
Expanding the understanding of tRNA lifecycle under cellular stress
Allison Williams · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2027 · career development · K99
The Role of Histone Cleavage in Breast Cancer
Zheqi Li · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2029 · research · R01
Computational methods for multiplex image analysis of the tumor microenvironment
William Edward Lotter · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2030 · research · R37
ACTIVATE: AI-driven Clinical Trial Information and Viability Assessment Tool for EHRs
Kenneth L Kehl · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2028 · fellowship · F31
Deciphering the mechanisms regulating itaconate production and signaling in macrophages
Nhien Tran · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2027 · research · R37
Liquid biopsy approaches to inform osteosarcoma prognosis and tumor evolution
Brian Crompton · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2026 · research · R01
Bioethics research to understand engagement in decision-making among adolescents and young adults with cancer at risk for health care disparities
Jennifer W Mack · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2028 · fellowship · F31
Unraveling the Mechanisms of Neoantigen Vaccine-Induced Epitope Spreading
Connor Antonio Richterich · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2030 · career development · K25
Resolving phenotypic overlap in renal carcinoma subtypes using multi-tiered network methods
Marouen Ben Guebila · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2029 · research · R01
Structural Basis of Thermogenic Mitochondrial Respiratory Complexes Assembly
Pere Puigserver · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2030 · program · P01
Convergent Epigenetic Control of Neuroendocrine Cancers
James A. Decaprio · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2027 · career development · K99
Revealing Cellular Determinants of LINE-1 Retrotransposition Outcomes
Cheuk-Ting Law · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2027 · fellowship · F32
Dissecting the Structure of Oligomeric BAK and the Implications for Reactivating Apoptosis in Cancer
Minh Thu H Ma · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2026 · career development · K99
Engineered Living Materials as Programmable Therapeutic Implants for Pancreatic Cancer
Tetsuhiro Harimoto · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2027 · career development · K99
Therapeutic Strategies to Prevent Small Cell Lung Cancer Histological Transformation
Yixiang Li · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2030 · research · R01
Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-making
Andre Bergman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2030 · cooperative agreement · U01
Impact of preanalytical conditions on functional cancer biomarkers
Patrick Bhola · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2028 · fellowship · F32
Elucidating the role of PATZ1 in MYCN-amplified neuroblastoma
Melinda Soeung · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2026 · grant · OT2
NexTGen - DFCI
Robbie G. Majzner · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2029 · research · R01
Calling germline and mosaic variants from long genomic and RNA-seq reads
Heng Li · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2028 · fellowship · F32
Examining the role of adenosine-sensing by macrophages in obesity-induced cardiac inflammation
Neil Sprenkle · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2032 · research · R35
New approaches to targeting cell cycle proteins for cancer treatment
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2028 · fellowship · F32
Interrogating the role of IFNgamma in promoting metastasis and immune evasion of triple negative breast cancer
Adam Joshua Getzler · Dana-Farber Cancer Institute · funded by National Institutes of Health
2025–2030 · program · P01
Epigenomics Core
Henry W. Long · Dana-Farber Cancer Institute · funded by National Institutes of Health
